UNSPSC 51181615: Dibromotyrosine

This classification denotes a tyrosine analog and non-essential amino acid with the molecular formula C9H9Br2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QD49LEP46E, chemically known as 3,5-dibromotyrosine but generally known as dibromotyrosine, which bears US NIH Compound Identifier 10833. European Medicines Agency schedules Dibromotyrosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13561MIG.

World Health Organization schedules dibromotyrosine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIBROMOTYROSINE remains the US FDA Preferred Term for this commodity. SMILES: BRC1CC(CC(N)C(=O)O)CC(BR)C1O.

UNSPSC 51181615 Dibromotyrosine, a Commodity code, covers pharmaceutical and OTC products procured through state and local cooperative purchasing vehicles and direct government contracts. State and local governments soliciting under this code are acquiring generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities—including health departments, correctional systems, state hospitals, county clinics, and municipal health agencies. The issuing bodies include state agencies administering cooperative purchasing alliances, which coordinate multi-state procurement to achieve volume pricing and standardized supply contracts. Vendors must meet rigorous regulatory and operational requirements: current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, FDA registration, contractual relationships with authorized wholesalers, EDI capability, comprehensive insurance (including $5 million commercial general liability), and pricing flexibility across flat, net, and WAC-minus formats. Contract awards typically span two years with optional extensions and encompass both new vendor onboarding and incumbent contract amendments.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline. MMCAP coordinates purchasing across Minnesota and participating jurisdictions including Oregon, distributing awarded vendors to three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Evaluation criteria weight price competitiveness at 75 percent, with smaller allocations for fixed pricing (10 percent), compliance with administrative fee formats (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). All products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026. Vendors face performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials. No specific budget or award values were disclosed; vendors should anticipate the 3 percent administrative fee applied to all contract purchases.